Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Prenetics Group ( (PRE) ) is now available.
On February 17, 2026, Prenetics Global Limited announced it had completed the sale of its 35% equity stake in cancer-screening venture Insighta to Tencent for $70 million in cash, marking the final step in a wider strategic overhaul. The deal lifts Prenetics’ total adjusted liquidity to $171.1 million as of February 15, 2026, including $99.3 million in cash and cash equivalents and $35.2 million in Bitcoin, while the company continues to operate with no debt.
Management framed the divestment as the most significant milestone in its transformation to streamline operations and concentrate resources on scaling IM8, its fast-growing global consumer health brand. The strengthened balance sheet, supported by non-dilutive capital from the Tencent transaction and prior asset sales, is expected to give Prenetics greater financial flexibility to fund IM8’s international expansion, product innovation and clinical trials, with further details to be discussed alongside its fourth-quarter and full-year 2025 results on February 18, 2026.
The most recent analyst rating on (PRE) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
Overall score is constrained by weak financial performance (ongoing losses and negative operating/free cash flow), partially offset by strong technical trend and momentum. Valuation remains unattractive due to negative earnings and no dividend support.
To see Spark’s full report on PRE stock, click here.
More about Prenetics Group
Prenetics Global Limited (Nasdaq: PRE) is a consumer health sciences company focused on advancing human health and longevity. Its flagship premium nutrition brand, IM8, co-founded with David Beckham and backed by top athletes, offers science-based daily supplements and has rapidly scaled to more than $100 million in annualized recurring revenue across over 30 countries.
Average Trading Volume: 197,526
Technical Sentiment Signal: Hold
Current Market Cap: $369.7M
Learn more about PRE stock on TipRanks’ Stock Analysis page.